Opko Health, Inc.

Good day and welcome to the OpcoHealth third quarter of 2024 financial results conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, please press star, then two. Please note this event is being recorded. I would now like to turn the conference over to Yvonne Briggs. Please go ahead.

Thank you, Operator, and good afternoon. This is Yvonne Briggs with Alliance Advisors Investor Relations. Thank you all for joining today's call to discuss Opco Health's financial results for the third quarter of 2024. I'd like to remind you that any statements made during this call by management, other than statements of historical fact, will be considered forward-looking and, as such, will be subject to risks and uncertainties that could materially affect the company's expected results. Those forward-looking statements include, without limitation, the various risks described in the company's SEC filings, including the annual report on Form 10-K for the year ended December 31, 2023. and in subsequently filed SEC reports. This conference call contains time-sensitive information that is accurate only as of the date of the live broadcast, November 7, 2024. Except as required by law, OPCO undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this call. Before we begin, let me review the format for today's call. Dr. Philip Frost, Chairman and Chief Executive Officer, will open the call. Dr. Elias Serhouni, Vice Chairman and President, will then provide an overview of BioReference Health as well as Opco's pharmaceutical business. After that, Adam Logel, Opco's CFO, will review the company's third quarter financial results and provide fourth quarter financial guidance, and then we'll open up the call to questions. Now I'd like to turn the call over to Dr. Frost. Good afternoon.

Good afternoon. and thank you for joining us today. We had a good third quarter with positive developments in both our diagnostics and pharmaceutical segments. Significant progress has been made to put bioreference on a clear path to profitability after selling certain assets to LabCorp. We continued the development of the MODX technology product portfolio. Pfizer has successfully launched NGINLA in all priority markets, And we continue to be enthusiastic about positive animal studies of our once-weekly injectable dual GLP-1 glucagon agonist program. Our collaboration with Interra Bio on an orally delivered, once-daily version of our oxyntamodulin also shows great promise in animal studies. We bolstered our balance sheet with significant cash infusions. to ensure adequate funding for our pharmaceutical pipeline, and to return capital to our shareholders through a stock repurchase program. As we continue to execute our strategy, we expect these important catalysts to ultimately be reflected in a closer alignment of the value of our assets and our stock price. Our current portfolio consists of a variety of segments that investors need to evaluate. We plan to operate these segments to drive value for Opco with additional partnerships, business development initiatives, and asset sales. We're confident in our business and strategy and will consider expansion of our shared buyback program as appropriate. Opco is structured around five key businesses. By reference, Modex, our growth hormone franchise with Pfizer, our global healthcare business, and our pipeline assets. We have the ability to explore partnerships and sales or business development activities with each in order to build value, unlock value, and return capital to OPCO. We've seen some evidence of this so far in 2024, and we hope to continue the process in 2025. We look forward to keeping you apprised of our progress. With that introduction, I'll turn the call over to Elias.